🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — July 17, 2026

The 16 filings for the S&P 500 Technology stream on July 17, 2026, are dominated by insider trading activity, with a clear bearish tilt from several high-level executives and directors executing pre-planned sales. The most notable signals come from AMD, Cadence, Palantir, and CrowdStrike, where C-suite and board members sold significant equity, while Adobe's filings reveal a concerted effort to retain top talent during a CEO transition through enhanced severance benefits. No period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A activity were present in these filings, limiting the depth of trend analysis. The overall sentiment is mixed, with defensive insider selling at key companies offset by neutral tax-withholding transactions across Adobe's leadership. The digest highlights a potential leadership retention risk at Adobe and a pattern of insider profit-taking at high-growth tech firms, which investors should monitor for broader sector sentiment shifts.

15 high priority 1 medium 16 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 17, 2026

The 15 filings for July 17, 2026, reveal a Nasdaq-100 portfolio with a clear dichotomy. Netflix's quarterly report shows robust top-line growth but with a mixed sentiment due to a significant QoQ cash flow decline and accelerating content spend, which may challenge near-term free cash flow narratives. The dominant insider activity is from Adobe, where a cluster of executives engaged in tax-withholding stock exercises (sell-to-cover) following the grant of a golden parachute retention package to the CLO, suggesting a routine but cautious leadership transition. Notably, two technology companies—AMD (CTO) and Palantir (Director)—executed sales under 10b5-1 plans, while AppLovin and Micron showed only negligible or tax-related insider movements. The key period-over-period trend is Netflix's soaring H1 2026 net income (+44.3% YoY) against a 28% QoQ operating cash flow dip, highlighting a potential divergence between accounting profitability and cash generation. No broad-based guidance changes were reported, making Netflix's capital allocation (aggressive $4.71B buybacks) the most material portfolio event.

14 high priority 1 medium 15 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 17, 2026

The July 17, 2026, batch of 50 SEC filings is dominated by routine, passive ownership disclosures from BlackRock, which filed 44 of the 50 reports. The overwhelming theme is the passive rebalancing and seeding of its own iShares ETF ecosystem, with BlackRock Portfolio Management LLC reporting significant, often majority, stakes in dozens of its own funds. This activity is non-actionable for activist or institutional strategy, as it reflects internal fund seeding and ordinary-course portfolio management, not a change in investment thesis. Outside of BlackRock, the filings reveal a few notable, non-activist positions: Pzena Investment Management disclosed a new 5.7% passive stake in Cognizant Technology Solutions, and Segra Capital Management revealed a 5.3% stake in X-Energy, Inc. A significant risk flag is the complete exit of Emirates Telecommunications (e&) from its position in Vodafone Group, signaling a strategic shift. The only filing with activist potential is the Schedule 13D for Columbus Circle Capital Corp III, a SPAC, detailing the sponsor's founder share structure and lock-up provisions, which is standard for the SPAC lifecycle. Overall, the digest provides minimal actionable intelligence for activist or institutional activity monitoring, as the vast majority of filings are passive and non-eventful.

1 high priority 49 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 17, 2026

The 17 filings from the S&P 500 Financials sector reveal a bifurcated earnings environment: large banks (Truist, Travelers) posted strong YoY profit growth (37% and 46% respectively), driven by surging investment banking fees and improved underwriting, yet face headwinds from NIM compression (-4 bps) and flat premium volumes. Insider activity is a major theme—multiple C-suite executives at Morgan Stanley, BlackRock, and Goldman Sachs sold shares, while Bank of America’s CEO Moynihan exercised and disposed of stock, signaling caution at the top. Capital allocation is aggressive: Travelers repurchased $3.1B in H1 2026 (up 313% YoY) and raised its dividend 13.6%, while Robinhood’s CFO sold under a 10b5-1 plan. The CMBS trust filing (Citi) is a non-event. Overall, the sector shows strong operational performance but insider selling and margin pressure warrant close monitoring.

14 high priority 3 medium 17 total filings
· daily

S&P 500 Energy Sector SEC Filings — July 17, 2026

The two filings from the S&P 500 Energy sector on July 17, 2026, present a mixed picture of routine governance and a minor insider buying signal. Targa Resources Corp. announced the appointment of an experienced energy executive to its board and audit committee, a neutral but positive governance move that strengthens oversight without immediate financial impact. Texas Pacific Land Corp saw a small purchase by a 10% owner, Horizon Kinetics Asset Management, at $416.05, which is a modest bullish signal but lacks the volume to indicate strong conviction. No period-over-period trends, forward-looking guidance, or capital allocation changes were reported in either filing, limiting the depth of sector-wide insights. The lack of material operational or financial data in these filings means the digest is constrained to governance and insider activity observations. Overall, the energy sector shows no significant new developments from these two filings, with the focus remaining on individual company actions rather than broader trends.

2 high priority 2 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — July 17, 2026

The two filings from the S&P 500 Consumer Staples sector on July 17, 2026, reveal a mixed insider activity picture, with a notable insider sale at Walmart and a routine tax-related transaction at Clorox. No period-over-period financial comparisons, forward-looking guidance, capital allocation changes, or transaction details were available in the enriched data for either filing, limiting the depth of trend analysis. The Walmart sale, executed under a Rule 10b5-1 plan, is a moderate bearish signal given the executive's significant remaining holdings, while the Clorox transaction is neutral and low materiality. Overall, the sector shows no clear bullish or bearish themes from these filings alone, but the insider sale at Walmart warrants monitoring for potential further insider activity.

2 high priority 2 total filings
· daily

S&P 500 Industrials Sector SEC Filings — July 17, 2026

The 34 filings for the S&P 500 Industrials stream on July 17, 2026, are dominated by two companies: Paychex and Republic Services, with no filings from other constituents like aerospace, defense, or machinery firms. Paychex's 10-K reveals a mixed performance with strong 17% YoY revenue growth to $6.5B, but significant margin pressure from a 19% expense increase and a 156% surge in interest expense to $269.5M, signaling potential profitability headwinds. Insider activity at Paychex is notable: the CEO received a $10.7M stock option grant, but the VP, Controller & Treasurer sold $303K in stock, indicating mixed management sentiment. Republic Services shows routine director and officer equity grants, with no insider sales or purchases, suggesting a stable, neutral outlook. The lack of filings from other industrial giants limits sector-wide trend analysis, but the data points to a focus on executive compensation and capital structure risks at Paychex, while Republic Services appears in a steady-state governance phase.

34 high priority 34 total filings
· daily

US Material Events SEC 8-K Filings — July 17, 2026

The July 17, 2026, filing cycle reveals a market dominated by significant capital markets activity, with a major IPO ($1.01B for Csquare), a large convertible note offering ($650M+ for Penguin Solutions), and a $1.14B ABS securitization by Uniti Group. The most critical development is the receivership of Fuse Science, a terminal event for a micro-cap, while the sector sees a major strategic pivot in biotech with Jasper Therapeutics' dilutive acquisition of Kira Pharmaceuticals. A clear theme of financial distress and restructuring is evident, with companies like Trans American Aquaculture restating financials, Generation Income Properties fighting for Nasdaq compliance, and EyePoint Pharmaceuticals settling a False Claims Act case. On the positive side, there is a wave of strategic M&A, including IPG Photonics' acquisition of Lumibird Medical and several SPACs (Four Leaf, Mercator) pursuing new combinations. Leadership changes are widespread, but the most impactful are the CFO transitions at Energy Vault and Lindsay Corp, and the CEO transition at Adobe, which is triggering retention packages. Overall, the period is characterized by aggressive capital raising, strategic repositioning, and a clear bifurcation between companies with strong growth narratives and those facing existential challenges.

50 high priority 50 total filings
· daily

Insider Trading Pulse — July 17, 2026

Today's insider trading pulse reveals a bifurcated market: large-scale institutional buying in Jefferies Financial Group ($319M) and John Hancock GA Mortgage Trust ($79M combined from Manulife entities) signals strong conviction in financials and mortgage credit, while notable insider selling in CIENA ($3M+ from CEO and senior VPs) and AEHR Test Systems ($1.64M from a director) raises caution in tech hardware. The period-over-period data shows a cluster of director stock awards across AptarGroup (7 directors, 151 shares each) and Ennis (3 directors, 2,661 each), indicating routine equity compensation rather than conviction signals. A standout bullish signal is Elevance Health's CEO Gail Boudreaux buying $753K of stock at ~$368, a rare open-market purchase by a healthcare CEO. Conversely, Wells Fargo's Chief Risk Officer gifting 67,966 shares (~$4.6M) may signal estate planning but warrants monitoring. The overall theme is mixed: financials and REITs see strong insider buying, while tech and retail see selling or neutral awards.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 17, 2026

The 9 filings for the Dow 30 stream reveal a stark divergence between Travelers' exceptional underwriting turnaround and minor insider selling at Goldman Sachs and Walmart. Travelers' Q2 2026 net income surged 46% YoY to $2.208B, driven by a 670 bps improvement in the combined ratio to 83.6%, reflecting lower catastrophe losses and favorable reserve development. However, net written premiums were flat, and Personal Insurance premiums declined 8% YoY, signaling competitive headwinds. Insider activity was muted but notable: a Goldman Sachs director gifted shares, its CAO sold ~$172K, and a Walmart EVP sold ~$331K under a 10b5-1 plan, all routine transactions. The key portfolio-level pattern is a mixed quality of earnings—Travelers shows strong profitability but stagnant top-line growth, while the financial sector insider moves are small and non-alarming. The most critical development is Travelers' massive $3.1B in share buybacks in H1 2026, up from $750M, signaling aggressive capital return.

8 high priority 1 medium 9 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 17, 2026

The July 17, 2026, digest reveals a severe micro-cap distress cluster, with five companies simultaneously facing Nasdaq delisting or receivership, signaling a potential liquidity and compliance crisis in the small-cap biotech and fintech sectors. Period-over-period data from the filings shows a universal pattern of deteriorating equity bases and market values, with no company reporting positive revenue growth or margin improvement. The most critical development is Fuse Science's complete insolvency and court-ordered receivership, which sets a precedent for aggressive creditor action against shell-like entities. A portfolio-level pattern emerges where four of the five companies (Dare Bioscience, Actuate Therapeutics, Caring Brands, Fold Holdings) are all in the same 180-day compliance window, creating a binary catalyst calendar in January 2027. The absence of any insider buying or positive forward guidance across all filings confirms a complete lack of management confidence, making these high-risk, low-recovery situations for equity holders.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — July 17, 2026

The July 17, 2026, filing set reveals a market dominated by corporate restructuring, insolvency proceedings, and strategic M&A, with a notable concentration of distress in Indian real estate and financial services. Key period-over-period trends include significant revenue declines from asset sales (Braemar Hotels: -18% pro forma revenue drop) and margin compression from regulatory penalties (Jana Small Finance Bank: 22.5% NPA divergence). The most critical developments are the appointment of a receiver for Fuse Science (insolvent, $0 assets), Nasdaq delisting threats for Actuate Therapeutics and Dare Bioscience, and a transformative 99% capital reduction at Oxford Industries following a change in control. Portfolio-level patterns show a surge in SPAC activity (4 IPOs/amendments) and a wave of Indian insolvency updates (7 filings), signaling a bifurcated market where capital is flowing to new blank-check vehicles while legacy entities face liquidation or restructuring. The overall sentiment is cautiously negative, with 18 filings carrying negative or mixed sentiment, but pockets of opportunity exist in renewable energy (DCM Shriram) and aerospace (NRB Bearing).

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 17, 2026

Across 50 SEC filings for July 17, 2026, three dominant themes emerge: (1) pronounced capital actions and M&A activity driving near-term catalysts (Dominion/NextEra S-4 filings, IPG/Lumibird bid, Jasper/Kira all‑stock + PIPE, multiple SPAC IPOs/extensions); (2) mixed financial performance across banks and industrials with earnings dispersion — regional banks show resilient fee income but margin pressure (Truist, Regions, Fifth Third), while select industrials/energy report restructuring charges and asset impairments (Autoliv, Frequency Electronics, BHP); (3) significant dilution and financing maneuvers at smaller growth/tech names (AITX reverse split and share regime changes, NovaBridge equity plan, multiple SPACs). Period-over-period comparisons show revenue growth >20% YoY in pockets (AITX device rental +37% driving +26% revenue YoY), while several companies report margin compression (Frequency Electronics gross margin down ~1,400 bps YoY to 29.1%). Material developments with market implications: Dominion/NextEra combination (expected close H2 2027) is the largest regulatory/catalyst event and may re-rate regulated utility exposures; Jasper/Kira transaction materially dilutes legacy holders but funds operations into 2H 2028 and creates a biotech pipeline with milestone CVR upside; IPG’s €300M Lumibird Medical offer is accretive to margin and expands medical laser exposure. Portfolio-level patterns: SPAC activity remains elevated (multiple new IPOs, unit separations, deadline extensions) signaling continuing sponsor-driven deal flow; insider moves are meaningful in select filings (Jefferies large buy by SMFG, exercises by directors) and indicate conviction in financials or compensation settlements. Immediate market actions should prioritize monitorable near-term catalysts (Dominion regulatory filings, IPG close expected Q4 2026, Jasper clinical milestones to 2028, MakeMyTrip Indian IPO process) while de-risking names with cash erosion, high short-term liabilities, or ongoing deregistration filings (Sigyn, AITX liquidity stress).

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 17, 2026

The single filing for eBay Inc. (EBAY) within the S&P 500 Consumer Discretionary stream reveals a major, high-conviction event: GameStop Corp. has disclosed a 9.8% beneficial ownership stake, acquired through a combination of open-market purchases and the physical settlement of a massive derivatives position. The total consideration of approximately $4.35 billion underscores a significant capital deployment by a fellow consumer discretionary company into a legacy e-commerce platform. This event creates a unique dynamic, blending activist-like positioning with potential strategic or financial motives. The filing's materiality is high (8/10), but the lack of period-over-period comparisons, insider trading, or forward guidance from eBay itself limits the breadth of traditional fundamental analysis. The key takeaway is the emergence of a new, influential shareholder with a history of disruptive moves, which could catalyze strategic changes at eBay.

1 high priority 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 17, 2026

The four filings from the S&P 500 Healthcare stream reveal a clear insider conviction signal in the managed care segment, with Elevance Health's CEO and a director making significant open-market purchases totaling over $1.1 million. This insider buying, occurring at a stock price near $366-368, suggests management sees the company as undervalued, especially given the CEO's already substantial 171,976-share holding. In contrast, the two Vertex Pharmaceuticals filings show routine director compensation in deferred stock units, carrying no market signal. The absence of any period-over-period financial comparisons, forward guidance, or capital allocation changes across these filings limits the ability to identify broader sector trends. The primary actionable insight is the concentrated bullish insider activity at Elevance Health, which warrants further investigation into the company's fundamentals and upcoming catalysts.

4 high priority 4 total filings
· daily

US Earnings Financial Results SEC Filings — July 17, 2026

This digest covers 10 filings with enriched data, revealing a market dominated by mixed earnings quality and diverging capital allocation strategies. While revenue growth is present across several companies (Netflix +13.4% YoY, Paychex +17% YoY, Cloudastructure +78% YoY), profitability is under severe pressure. A clear theme of 'growth at a cost' emerges, with operating expenses and interest costs surging, compressing margins for Autoliv, Paychex, and Frequency Electronics. The most critical development is the aggressive capital return programs at Travelers ($3.1B buybacks, +13.6% dividend) and Netflix ($4.71B in Q2 buybacks), signaling strong management confidence despite operational headwinds. Conversely, micro-cap companies like Winning Catering and Snow Rothschild show extreme financial fragility with zero cash and negative equity. Insider activity data was notably absent from these filings, limiting one key signal source, but the period-over-period comparisons and forward-looking statements provide a rich tapestry of actionable intelligence. The overall picture is one of a bifurcated market where large caps are returning capital aggressively, while smaller and mid-cap firms struggle with rising costs and margin compression, creating both risks and potential turnaround opportunities.

10 high priority 10 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 17, 2026

This intelligence stream covers six SEC proxy filings from July 17, 2026, spanning blank-check companies (Cartesian Growth Corp II, SilverBox Corp IV), a regional bank (Riverview Bancorp), and three biotech/life-sciences firms (Tempest Therapeutics, Tivic Health Systems, Glucotrack). The dominant theme is corporate survival and restructuring: two SPACs seek deadline extensions to consummate deals, two micro-cap biotechs propose reverse stock splits to maintain Nasdaq listings, and one biotech seeks governance changes to eliminate supermajority voting. Period-over-period data is sparse across these filings, as most are special-meeting proxies rather than annual reports with financial comparisons. However, insider ownership is notably high in the SPACs (Cartesian: ~65.1% insider voting power), and insider trading activity is absent in all filings—no CEO or CFO transactions were reported. The most material development is Tivic Health's existential Nasdaq delisting risk (stock at $0.52, 90% below the $1.00 threshold), while Glucotrack's post-merger reverse split (up to 1-for-30) signals aggressive capital structure restructuring. No sector-wide trends emerge given the diverse company types, but a common thread is shareholder dilution risk across three of the six companies. The overall sentiment is neutral-to-negative, with no bullish signals identified.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 17, 2026

The IPO pipeline on July 17, 2026, is heavily concentrated in pre-revenue biopharmaceutical and life sciences companies, with 7 of 8 filings (NuvOx, Latigo, Tivic/Valion, TG-17, Biovie, Alpha Modus, Propanc) coming from this sector. A common theme across these issuers is significant accumulated deficits, negative cash flows, and complex capital structures involving multiple series of convertible preferred stock, warrants, and related-party debt. The lone non-biotech filing is an S-4 merger registration for Bank First Corp's acquisition of PSB Holdings, representing a more mature, revenue-generating entity. Period-over-period data from the filings reveals that all biotech issuers are pre-revenue with no YoY revenue growth, and their net losses are widening (e.g., Biovie's net loss of $12.5M for the nine months ended March 31, 2026). Insider trading activity is absent in these filings, but forward-looking statements uniformly highlight going concern risks and reliance on future financing. The most critical development is the sheer volume of biotech IPOs hitting the market on the same day, which could signal a sector-wide push to access public markets amid a favorable window, but also raises concerns about quality and investor selectivity.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — July 17, 2026

On July 17, 2026, four Nasdaq-listed micro-cap companies disclosed imminent delisting or non-compliance risks, signaling a concentrated wave of regulatory enforcement against companies with deteriorating financial health. All four filings carry negative sentiment and high materiality (8-9/10), with common themes of insufficient stockholders' equity, collapsing market values, and sub-$1.00 bid prices. Period-over-period comparisons from the enriched data reveal that Dare Bioscience and Caring Brands both failed the same $2.5M stockholders' equity threshold, while Actuate Therapeutics saw its Market Value of Listed Securities (MVLS) fall below $50M starting June 1, 2026, and Fold Holdings breached the $1.00 minimum bid price for 30 consecutive days. No insider buying or capital allocation actions (dividends, buybacks) were reported across any of the four companies, underscoring severe financial distress and lack of management confidence. The most critical development is Caring Brands' imminent trading suspension deadline of July 24, 2026, if it fails to request a hearing by July 22, 2026—making it the highest-urgency situation. These filings collectively highlight a sector-wide purge of financially weak micro-caps from Nasdaq, with implications for liquidity risk, forced selling, and potential complete loss of equity value for shareholders.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — July 17, 2026

This digest of 42 filings reveals a significant wave of executive and board-level changes across US-listed companies, with a notable concentration in the small-cap and micro-cap space. Key themes include a high volume of CFO departures and appointments, several board refreshments bringing in specialized expertise (e.g., sustainable investing, SPAC experience), and a few instances of leadership transitions tied to M&A or strategic pivots. Period-over-period data is largely absent from these event-driven filings, but forward-looking statements and insider activity provide actionable insights. The most critical developments include a CFO appointment at Energy Vault from a top-tier firm, a CEO salary increase at Star Group, and a leadership overhaul at Raphael Pharmaceutical, which carries the highest risk. Overall, the period is characterized by routine governance changes, but several filings present clear bullish or bearish signals for investors.

42 high priority 42 total filings